StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen EPOGEN (epoetin alfa by Quarter

EPOGEN (epoetin alfa — Dialysis Anemia, legacy standalone disclosure) — Worldwide reported sales growth YoY (%) (%)

QuarterlyAnnual

Amgen EPOGEN (epoetin alfa: -65.0% in Q4 2024, down 13.0 pts from a year earlier. That is the lowest of the 26 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2024
-65.0%
Period ended Dec 31, 2024
Change on a year earlier
-13.0 pts
-52.0% in Q4 2023
History
26 quarters
Since Q3 2018
Sources
26
Documents cited below

Where the Q4 2024 figure comes from

“|| EPOGEN ® | 19 | — | 19 | 55 | (65%)”

Source: Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗

Reported in Form 8-K Product Sales Detail by Product and Geographic Region.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEPOGEN (epoetin alfa — Dialysis Anemia, legacy standalone disclosure) — Worldwide reported sales growth YoY (%) (%)Year on yearSource
Q4 2024Dec 31, 2024-65.0%-13.0 ptsForm 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 2024-34.0%+29.0 ptsForm 8-K (amgn-20240930earningsrelea.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 2024-48.0%+7.0 ptsForm 8-K (amgn-20240630earningsrelea.htm, filed 2024-08-06) ↗
Q1 2024Mar 31, 2024-32.0%+18.0 ptsForm 8-K (amgn-20240331earningsrelea.htm, filed 2024-05-02) ↗
Q4 2023Dec 31, 2023-52.0%-41.0 ptsForm 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 2023-63.0%-62.0 ptsForm 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Q2 2023Jun 30, 2023-55.0%-60.0 ptsForm 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 2023-50.0%-46.0 ptsForm 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 2022-11.0%-7.0 ptsForm 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 2022-1.0%+6.0 ptsForm 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗
Q2 2022Jun 30, 20225.0%+24.0 ptsForm 8-K (amgn-2022630earningsrelease.htm, filed 2022-08-04) ↗
Q1 2022Mar 31, 2022-4.0%+15.0 ptsForm 8-K (amgenq12022earningsrelease.htm, filed 2022-04-27) ↗
Q4 2021Dec 31, 2021-4.0%+33.0 ptsForm 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗
Q3 2021Sep 30, 2021-7.0%+24.0 ptsForm 8-K (amgn-2021930xq3ex991.htm, filed 2021-11-02) ↗
Q2 2021Jun 30, 2021-19.0%+9.0 ptsForm 8-K (amgn-2021630xq2ex991.htm, filed 2021-08-03) ↗
Q1 2021Mar 31, 2021-19.0%+10.0 ptsForm 8-K (amgn-2021331xq1ex991.htm, filed 2021-04-27) ↗

Cite this data

StockData. (2026). Amgen EPOGEN (epoetin alfa (%), quarterly Q3 2018–Q4 2024 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-epogen-yoy

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.